Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors.
暂无分享,去创建一个
R. Sullivan | K. Flaherty | J. Sosman | A. Tolcher | A. Ribas | S. Patel | M. Sznol | A. Varghese | F. Janku | H. Burris | J. Infante | S. Saha | R. Carvajal | A. Wang-Gillam | D. Welsch | D. Wong | M. Patel